Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42153630.
- Also identified by DOI 10.1021/acsnano.5c13784.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer vaccines are designed to activate dendritic cells (DCs), which are potent antigen-presenting cells that initiate antigen-specific adaptive immune responses and inhibit tumor growth. Microneedles (MNs) have emerged as a promising cancer vaccine platform, enabling the noninvasive dermal delivery of cancer antigens and adjuvants to activate dermal DCs. However, conventional solid MNs have a limited surface area, restricting the adsorption of large amounts of bioactive components. Therefore, 3D-printed lattice-structured microarray patches (L-MAPs) with an increased surface area were designed in this study, which permitted the enhanced adsorption of cancer nanovaccines compared to conventional solid microarray patches. L-MAPs were fabricated by using the continuous liquid interface production (CLIP) technology, facilitating the rapid printing of MNs with lattice structures. L-MAPs adsorbed higher amounts of mesoporous-silica-based nanovaccine (MV) on their needle surfaces, exhibiting greater dermal vaccine delivery capacity. Applying MV@MAPs on mouse skin led to efficient DC recruitment, maturation, and subsequent antigen-specific T cell responses in vivo. Consequently, the resulting antitumor immune response considerably suppressed the tumor growth. This approach highlights that using CLIP-printed L-MAPs is a promising strategy for efficient nanovaccine delivery in cancer immunotherapies.